AstraZeneca partners with Imperial’s VaxEquity to bolster its self-amplifying RNA based drugs pipeline

AstraZeneca has inked a deal with VaxEquity, a firm producing experimental COVID-19 vaccine of U.K.’s Imperial College, to develop and market drugs...

FDA rejects AstraZeneca and FibroGen’s roxadustat NDA for CKD related anemia

FibroGen and AstraZeneca new drug application (NDA) for roxadustat to treat anaemia associated with chronic kidney disease (CKD) has been rejected by...

AstraZeneca and FibroGen hit FDA committee’s safety data firewall for roxadustat

Two roxadustat partners AstraZeneca and FibroGen have received objections regarding safety concerns of their drug from the FDA after which the two companies

Japan’s MHLW approves AstraZeneca and Moderna Covid-19 vaccines

Japan’s Ministry of Health, Labour, and the Welfare department (MHLW) has approved Moderna’s COVID-19 mRNA vaccine and Vaxzevria

AstraZeneca gets US FTC clearance to acquire rare disease therapy company Alexion

The suggested $39 billion acquisition of Alexion Pharmaceuticals, a company of rare disease therapy, by AstraZeneca has been approved by the US Federal Trade Commission (FTC).

AstraZeneca and Aji Bio-Pharma Expand Mfg. Agreement

Ajinomoto Bio-Pharma Services, a provider of biopharmaceutical contract development and manufacturing services

Latest news

Orion signs $16 million deal with Jemincare for development of novel non-opioid pain treatment

The deal involves a $16 million payment from Orion to Jemincare with milestones as well as royalty...
- Advertisement -

Several drug recalls hit the US market, including Pfizer’s Accupril

Leading pharmaceutical companies have been hit by recalls recently. These U.S. based drugs  include Jubilant’s Methylprednisolone ,...

Why Focus on Treating Diseases Instead of Curing Them?

It’s a tragic irony: So much money has been poured into treating diseases, but far less into...

Must read

Surrounded by controversy, FDA approves Biogen’s Alzheimer’s drug Aduhelm

In the middle of the debate about the Alzheimer’s drug approval, the United States FDA has authorized Aduhelm

Amgen’s KRAS drug gets early FDA approval for lung cancer with specific mutation

On Friday, the United States FDA (Food and Drug Administration) has authorized a medication of Amgen Biopharmaceutical in patients with NSCLC